Almirall, S.A. (BME:ALM)
12.40
+0.34 (2.82%)
Apr 8, 2026, 9:16 AM CET
Almirall Employees
Almirall had 2,108 employees as of December 31, 2025. The number of employees increased by 82 or 4.05% compared to the previous year.
Employees
2,108
Change (1Y)
82
Growth (1Y)
4.05%
Revenue / Employee
€528,715
Profits / Employee
€21,895
Market Cap
2.59B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,108 | 82 | 4.05% |
| Dec 31, 2024 | 2,026 | 122 | 6.41% |
| Dec 31, 2023 | 1,904 | 58 | 3.14% |
| Dec 31, 2022 | 1,846 | 60 | 3.36% |
| Dec 31, 2021 | 1,786 | -1 | -0.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Grifols | 25,258 |
| Laboratorios Farmaceuticos Rovi | 2,045 |
| Atrys Health | 2,016 |
| Faes Farma | 1,894 |
| Clínica Baviera | 1,861 |
| Laboratorio Reig Jofre | 1,512 |
| Prim, S.A. | 902 |
| Pharma Mar | 505 |
Almirall News
- 12 days ago - AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne - Business Wire
- 16 days ago - Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology - Business Wire
- 26 days ago - Spain's Almirall in talks with 'dozens' of firms to license China assets, CEO says - Reuters
- 27 days ago - Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships - Business Wire
- 6 weeks ago - Almirall profit quadruples in 2025 as dermatology fuels growth push - Invezz
- 2 years ago - Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio - Business Wire